Notices and Reminders
Updated OUHSC COVID-19 Response Plan: Please see attached the updated OUHSC COVID-19 Response Plan, effective September 22, 2021. Substantive changes are summarized below:
Classrooms - Masking is required in classrooms located in patient care areas and in facilities where the primary function is patient care. Masking is expected in all other classrooms as well.
Positive Cases in the Classroom - Faculty who become aware that a student who has been attending class in a non-patient care area It is presumed that students attending class in patient care areas/facilities where patient care is the primary function are already masking in accordance with this Response Plan. has tested positive for COVID-19 two days before or after the last class meeting will:
- Continue holding in-person classes and
- Require all students in the class to wear masks for two weeks from the date of the positive student’s last attendance.
The student who tested positive will observe the quarantine period established by Student & Employee Health.
It is presumed that students attending class in patient care areas/facilities where patient care is the primary function are already masking in accordance with this Response Plan.
ORA Reminder: Effective October 1st, ORA requires applicants and recipients to use the updated Other Support format to submit with applications, Just-In-Time (JIT) and Research Performance Progress Reports (RPPRs).
Because of the substantial changes and additional information that needs to be included, all Key Personnel on RPPRs are expected to provide Other Support in the updated format for each RPPR, regardless of when Other Support was last submitted for key personnel. Failure to follow the appropriate format on or after October 1st, may delay processing your application/award by the ORA staff.
ORA Reminder: As a friendly reminder, please make sure you are carefully checking PeopleSoft and the budget justification to make sure OU Norman personnel are not included in the OUHSC personnel line. Failure to properly list the OUHSC vs Norman personnel in the budget preparation phase may result in a rebudget request from the sponsor, and could negatively impact processing of the award.
Requirements for Acknowledging NIH-Supported Research
NIH funded researchers are required to accurately acknowledge NIH funding in publications, press releases, or other documents about research that is funded by NIH in whole or in part. To comply with NIH requirements, recipients must include the following (as described in Communicating and Acknowledging Federal Funding):
Recipients should only acknowledge NIH awards on publications and other documents when the research activities that contributed to that publication directly arise from the award and are within the scope of the award being acknowledged. Please see the Communicating and Acknowledging Federal Funding and FAQs pages for more information on when, where, and how to acknowledge NIH funding.
NSF has released the updated Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 22-1). This is effective for proposals submitted or due on or after October 4, 2021. Please see the list of PAPPG (NSF 22-1) significant changes and clarifications for all of the updates. Some of the key changes are listed below:
Workshops and Seminars
Save the Date - ORA Noon Conference offered via Zoom
Date: November 30, 2021 at 1:00 pm
Topic: Writing Successful Grants
Description: This talk goes beyond the basics of grant writing to discuss writing the specific aims and considerations for the research strategy, convey the NIH-recommended format and approach for each subsection, address and explain core-review criteria, and discuss scoring conventions, rigor, and reproducibility.
OUHSC Funding Opportunities
Presbyterian Health Foundation (PHF) Bridge Grant Program Cycle III Request For Applications
Deadline: November 10, 2021
Description: The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications and provides critiques. This program can provide funding for up to $75,000 for one year. Guidelines and Application Form are attached for or can be found here. If you have any questions, please email ORA4PHF@ouhsc.edu
Link to Full Announcement: https://research.ouhsc.edu/Resources/PHF-Funding-2021
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email email@example.com or firstname.lastname@example.org).
- Deutscher Technologiedienst is seeking technology approaches for non-invasive early diagnosis of pathological cardiovascular conditions using medically relevant biomarkers (e.g., lactate, glucose, troponin, triglycerides). Submission entails a 1-pg non-confidential summary of technology (deadline 10/13).
- Johnson & Johnson Innovation is seeking technologies focused on the mechanism of exosome uptake in the GI tract with a view of applying this knowledge to the oral delivery of macromolecules. Preference is for technologies with data demonstrating in vitro transport correlates with in vivo transport and any species differences is advantageous. Submission entails a 1-pg non-confidential summary of technology (deadline 10/14).
- A global pharmaceutical company (requested anonymity) is seeking a range of collaboration opportunities for therapeutic targets and/or assets that target myeloid malignancies, specifically AML, MDS, MPN. Specific pathways of interest include pro-apoptotic pathways, epigenetic targets, differentiation of myeloid malignant cells, tumor specific membrane targets, and splicing regulators. Submission entails a 1-pg non-confidential summary of technology (deadline 10/21).
- Benitec Biopharma is seeking a range of collaboration opportunities with academia focused on monogenic targets that can be downregulated by expressed RNAi and replaced with RNAi insensitive transgene. Submission entails a 1-pg non-confidential summary of technology (deadline 10/28).
New Clinical Study Opportunities (Please note this is NOT a solicitation for study subjects)
Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:
- Clinical Trial Opportunity in Sickle Cell Disease study - IQVIA Biotech LLC
- Valo Health Phase 2 Cardiovascular Trial For Post-Myocardial Infarction Patients
- Phase 2 Acute Myeloid Leukemia (AML) Clinical Trial
Please contact Scott Davis at email@example.com if you would like to receive more information on any of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the Office of Research Administration.
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
Other Funding Opportunities
Cystic Fibrosis Foundation
The Fall 2021 RFAs for Research Grants, Pilot & Feasibility, Post-Doctoral Research Fellowships and Postdoc-to-Faculty Transition Awards for both the Research and Research Training and Path to a Cure - Academic Programs will be published in October, with a deadline of December 9, 2021!
Additional Open Funding Opportunities can be found here.
The Mselanoma Research Alliance (MRA) 2021-2022 Request for Proposal
Team Science Award Letters of Intent Due: October 6, 2021
Young Investigator Award Eligibility Checklist Due: November 3, 021
Young Investigator and Pilot Awards Full Proposals Due: November 17, 2021
Team Science Award Full Proposals Due (from invited applicants) Due: January 19, 2022
Description: MRA anticipates supporting at least $12.8 million in new funding. Proposals will be accepted for Team Science, Academic-Industry Partnership, Young Investigator, and Pilot Awards. Special Opportunities are also available in immunotherapy, women in research, and patient-centric clinical trials. MRA encourages applications from a diverse pool of investigators. Full descriptions of each award opportunity offered, including all Special Opportunity Awards, as well as eligibility criteria and instructions can be found on the MRA website at CureMelanoma.org/RFP
Proposals should be submitted via the proposalCENTRAL online application tool: https://proposalcentral.com/
OKLAHOMA NSF EPSCoR Summer 2022 Research Experience for Undergraduate Students (REU)
Description: OKLAHOMA NSF EPSCoR REU awards provide opportunities for undergraduate students from regional universities and colleges across the state to perform research in collaboration with Oklahoma’s comprehensive research campuses (OU, OSU, TU, NRI) during the summer months. The goal of the program is to enhance pursuit of graduate degrees by students at regional undergraduate institutions and strengthen network collaborations across all higher education institutions in Oklahoma. Students benefit from hands-on research experiences in STEM fields and one-on-one guidance from faculty mentors. Proposals will be awarded via a competitive review process based on proposal integrity and the engagement of a diversity of students from regional institutions.
Proposals Due: November 17, 2021
Link to Full Announcement: http://www.okepscor.org/2022-research-experience-undergraduates
Oklahoma Center for Adult Stem Cell Research (OCASCR)
Microbiome Interactions with the Nervous System in Health and Disease
Email Kellyfirstname.lastname@example.org for more information.
Grant Deadline: January 2022